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Rapid and robust generation of 
long-term self-renewing human 
neural stem cells with the ability 
to generate mature astroglia
Thomas Palm1,*, Silvia Bolognin2,*, Johannes Meiser2, Sarah Nickels2, Claudia Träger1, 
Ralf-Leslie Meilenbrock1, Johannes Brockhaus3, Miriam Schreitmüller3, Markus Missler3,4 & 
Jens Christian Schwamborn1,2
Induced pluripotent stem cell bear the potential to differentiate into any desired cell type and 
hold large promise for disease-in-a-dish cell-modeling approaches. With the latest advances in the 
field of reprogramming technology, the generation of patient-specific cells has become a standard 
technology. However, directed and homogenous differentiation of human pluripotent stem cells into 
desired specific cell types remains an experimental challenge. Here, we report the development of a 
novel hiPSCs-based protocol enabling the generation of expandable homogenous human neural stem 
cells (hNSCs) that can be maintained under self-renewing conditions over high passage numbers. Our 
newly generated hNSCs retained differentiation potential as evidenced by the reliable generation 
of mature astrocytes that display typical properties as glutamate up-take and expression of 
aquaporin-4. The hNSC-derived astrocytes showed high activity of pyruvate carboxylase as assessed 
by stable isotope assisted metabolic profiling. Moreover, using a cell transplantation approach, we 
showed that grafted hNSCs were not only able to survive but also to differentiate into astroglial 
in vivo. Engraftments of pluripotent stem cells derived from somatic cells carry an inherent tumor 
formation potential. Our results demonstrate that hNSCs with self-renewing and differentiation 
potential may provide a safer alternative strategy, with promising applications especially for 
neurodegenerative disorders.
Recent advances in the field of somatic cell reprogramming have enormously furthered the use and 
optimization of pluripotent stem cells (iPSCs) since the seminal studies by Yamanaka and coworkers1,2. 
Despite enormous progresses have been made in the methods for efficiently generating hiPSCs, their 
directed differentiation into a specific cell type remains technically challenging. This limited ability to 
generate pure specific cell populations renders the clinical use of pluripotent-derived cells still an obstacle.
The utilization of somatic fate restricted stem cells may be an alternative to achieve faster and more 
homogenous differentiation into the desired terminally differentiated cell types. It has been shown in 
mice that primary neural stem cells (NSCs) bear the advantage of being expandable while maintaining 
their neurogenic and gliogenic differentiation potential3,4. Therefore, the use of hiPSC derived hNSCs as 
a source for glia cells and neurons represents a promising strategy5. Stable cultures of hNSC may avoid 
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time and cost consuming maintenance of pluripotent stem cells as well as potential immune rejection 
and teratoma formation6.
Particularly interesting is the possibility of generating human astrocytic cultures starting from the 
same precursor cells used to generate neurons. Traditionally, astrocytes were solely described as support-
ing elements for neurons. Now, astrocytes are recognized as essential players involved in brain informa-
tion processing7–10. Alteration of their functions has emerged as a clear factor in disease pathogenesis, 
especially for neurodegenerative diseases. Additionally, increasing data support the critical role of astro-
glia in disease progression. As an example, it has been shown that glia cells have a direct, non-cell auton-
omous effect on motor neuron survival in a mouse model of amyptrophic lateral sclerosis11. Despite this 
growing evidence, astrocytes are less investigated compared to neurons. The lack of an acknowledged 
and well-characterized set of human astroglial markers and the difficulty to obtain cultures of human 
astrocytes under defined conditions is partly accounting for that.
Optimizing robust and reproducible protocols for the derivation of multiple cell types is clearly nec-
essary to fully explore the enormous potential offered by iPSC technology. Several human iPSC lines 
derived from patients suffering from different diseases have been generated, including Parkinson´s dis-
ease12 (PD), Alzheimer´s disease13 and schizophrenia14,15. Gene-editing approaches have been used to 
correct genetic mutations on PD patient derived-iPSC, resulting in the successful reversal of pathological 
phenotypes12. As iPSCs are derivable in a patient-specific manner, they are suitable for autologous engraft-
ments16 and for personalized disease modeling17. iPSCs might also offer a powerful tool in preclinical 
research to test both toxicity and efficacy of new drug candidates. Basing preclinical tests directly on the 
target human cells rather than on surrogate cell models, often from other rodents, hold the promise of 
leading to more efficient drug screening18. Notably, in the field of neurodegenerative diseases, hundreds 
of compounds have been successfully used in animal models to ameliorate induced-neuropathology 
or cognitive deficits. Yet this has not translated into effective disease-modifying therapies for humans. 
Obviously, differences between rodent and human physiology impede translation of rodent results to 
humans19. Thus, the possibility of testing drug candidates on patient-specific cells is of fundamental 
importance for diseases such as neurodegenerative disorders, which only affect humans.
A second application of iPSC is replacement therapies20,21. The use of iPSCs overcomes the legal/eth-
ical concerns as well as the risks of immune rejection of human embryonic stem cells (hESCs). Despite 
these advantages, iPSCs, as well as hESCs, have the inherent potential for teratoma formation6.
In this study, we describe the robust and rapid generation of hNSCs from hiPSCs. Furthermore, 
their maintenance and directed differentiation is described. In contrast to most other NSC studies we 
focus on a detailed characterization of human astroglial differentiation. We put a specific emphasis on 
the generation of long-term expandable human astrocyte cultures, which can be of use for modeling of 
disease-specific pathological traits.
Materials and Methods
Cell culture. iPSC from 3 individuals were cultured in feeder-free maintenance media (mTeSR, 
StemCell Technologies) and detached from plates using dispase (1 mg/mL) for 30min at 37 °C with the 
help of a scraper in case of big colonies. Colonies were collected by sedimentation and resuspended in 
“EB Medium”: Knockout™ DMEM (Gibco), 20% Knockout™ SR (Gibco), NEAA (Gibco), penicillin/
streptomycin (Invitrogen) and ß-mercaptoethanol (Gibco) supplemented with 10 μ M SB-431542 (Ascent 
Scientific), 1 μ M dorsomorphin (Tocris), 3 μ M CHIR 99021 (Axon Medchem) and 0.5 μ M PMA (Alexis). 
48 hours later, the medium was replaced by N2B27 medium (DMEM-F12 (Gibco)/Neurobasal (Gibco) 
50:50 supplemented with 1:200 N2 supplement (Invitrogen), 1:100 B27 supplement lacking vitamin A 
(Invitrogen), penicillin/streptomycin and glutamine (Invitrogen) supplemented with 10 μ M SB-431542, 
1 μ M dorsomorphin, 3 μ M CHIR 99021 and 0.5 μ M PMA. After additional 48 hours, the medium was 
replaced by N2B27 medium supplemented with 3 μ M CHIR 99021, 0.5 μ M PMA and 150 μ M ascorbic 
acid (Sigma Aldrich). Two days later, neural tube like structures were disintegrated by pipetting and 
small pieces were plated on Matrigel (BD Biosciences) coated 12-well plates in N2B27 medium sup-
plemented with 3 μ M CHIR 99021, 0.5 μ M PMA and 150 μ M ascorbic acid. At day 8, the medium was 
exchanged by N2B27 medium supplemented with 3 μ M CHIR 99021, 0.5 μ M PMA, 150 μ M ascorbic 
acid and 20 ng/ml basic (b) FGF (Peprotech). At day 12, cells were detached using dispase and cultivated 
in hNSC Maintenance Medium on Matrigel coated 10cm dishes. “Human NSC Maintenance Medium” 
was composed by DMEM HAM’s F12 medium (Gibco) supplemented with 40ng/ml EGF (Peprotech), 
40 ng/ml bFGF, N2 supplement, B27 supplement (with vitamin A), glutamine, Penicillin/Streptomycin 
and hLIF (1.5 ng/ml). Human NSCs were splitted (1:2 ratio) at a confluence of 70–80% by using dispase.
At a confluence of 70–80% the hNSC Maintenance Medium was switched to “Neuron differentiation 
medium” which was composed by N2B27 Medium supplemented with 10 ng/mL BDNF (Peprotech), 
10 ng/mL GDNF (Peprotech), 1 ng/mL TGF-β 3 (Peprotech), 200 μ M ascorbic acid and 500 μ M dbcAMP 
(Sigma Aldrich). Cultures were tested/harvested after 4 weeks of neuronal differentiation. Astrocytic 
differentiation was induced by switching the hNSC Maintenance Medium to the basic medium (DMEM 
HAM’s F12 medium, glutamine, Penicillin/Streptomycin) supplemented with 1% FCS (Gibco)3,4. Finally, 
multilinear differentiation was achieved by replacing the maintenance medium by the basic medium 
containing 10% of FCS.
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Immunocytochemistry. For immunohistochemical analysis, cells were fixed with 4% paraformalde-
hyde (PFA) in 120mM phosphate buffer (PBS), pH 7.4, permeabilized with 0.05% Triton X-100 in PBS, 
blocked with 10% goat serum in PBS and subjected to immunohistochemistry staining with primary and 
secondary antibodies diluted in the blocking solution.
For immunolabelling the following antibodies at indicated dilutions were used: anti-Nestin (1:400; 
BD Bioscience), anti-Sox1 (1:100; R&D Systems), anti-Sox2 (1:200; Abcam), anti-Pax6 (1:200; DSHB), 
anti-Ki67 (1:200; Vector Labs), anti-TuJ1 (1:400; Covance), anti-Map2 (1:200; Millipore), anti-DCX 
(1:200; Millipore), anti-GFAP (1:200; Millipore), anti-O4 (1:50, Sigma-Aldrich), anti-GABA (1:200, 
Abcam), anti-vGlut1 (1:200; Millipore), anti-TH (1:100, Millipore), anti-Synaptophysin (1:100; Millipore), 
anti-PSD95 (1:200; Invitrogen), anti-vimentin (1:5000; Abcam), anti-S100β (1:1000; Sigma-Aldrich), 
anti-aquaporin 4 (AQP4, 1:100; Santa Cruz Biotechnology) and anti-excitatory amino acid transporter 2 
(EAAT2, 1:100; Santa Cruz Biotechnology), secondary Alexafluorophore-conjugated antibodies (1:1000, 
Invitrogen). DNA was stained using Hoechst 33258 (1:10000, Invitrogen). All cells expressing a particular 
marker were counted manually and normalized to the total number of cells.
Microarray. mRNA was extracted from hiPSCs, hNSCs and derived cells using the RNAeasy kit 
(Quiagen) following manufacturer’s recommendations. mRNA quantity and purity were determined by 
using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies). Additional quality check 
was performed by the Agilent Bioanalyzer (Agilent). Gene expression profiles were generated using 
HumanGene 2.0ST arrays according to manufacturer’s recommendations (Affymetrix).
Bioinformatics. Correspondence analysis (CoA) from the TIGR MeV (MultiExperimentViewer; 
http://www.tm4.org/mev/) expression analysis platform was performed on the whole transcriptome 
established by the HumanGene 2.0ST arrays after RMA normalization proposed by the Affymetrix 
Expression Console.
GeneOntolgy (GO) analysis was performed on the 1428 transcripts specifically differing hNSCs from 
parental hiPSCs and from filial hMLDCs by a 2-fold difference. Here, we used the GO–biological pro-
cess analyzer implemented in the DAVID analysis platform (http://david.abcc.ncifcrf.gov/)22. GO terms 
and associated p-values (0.05 or lower) were then introduced into the REVIGO webserver23 to establish 
network files. These files were than uploaded to the cytoscape software where the final GO-Network was 
built up (www.cytoscape.org)24.
RT-qPCR. For quantification analysis, total RNA (mRNAs and miRNAs) was extracted from hiPSCs, 
hNSCs, human neurons (4 weeks of differentiation) and human astrocytes (6weeks of differentiation) 
by the RNAeasy kit (Quiagen) following manufacturer’s recommendations. Gene expression levels were 
evaluated by the SYBR-Green Jump Start Taq Ready Mix (Sigma-Aldrich) following manufacturer’s rec-
ommendations. Gene-related intensity levels were evaluated upon normalization with GAPDH levels. 
The following primers were used:
GAPDH: GTGGACCTGACCTGCCGTCT, GGAGGAGTGGGTGTCGCTGT
OCT4: CCTCACTTCACTGCACTGTA, CAGGTTTTCTTTCCCTAGCT
NANOG: TGAACCTCAGCTACAAACAG, TGGTGGTAGGAAGAGTAAAG
SOX2: CCCAGCAGACTTCACATGT, CCTCCCATTTCCCTCGTTTT
Ki67: ATACGTGAACAGGAGCCAG, CCTTGGAATCTTGAGCTTTCTC
SOX1: AATTTTATTTTCGGCGTTGC, TGGGCTCTGTCTCTTAAATTTGT
NESTIN: CTGGAGCAGGAGAAACAGG, TGGGAGCAAAGATCCAAGAC
PAX6: ATGTGTGAGTAAAATTCTGGGCA, GCTTACAACTTCTGGAGTCGCTA
GFAP: CTGCTCAATGTCAAGCTGG, AATGGTGATCCGGTTCTCC
MAP2: GGAGACAGAGATGAGAATTCCT, GAATTGGCTCTGACCTGGT
TH: GTGCTAAACCTGCTCTTCTC, TTCAAACGTCTCAAACACCT
SLC6A11 (GABA): CAACAACTGCTACAGGGAC, GAGAAGATGGCAAACCCAG
SLC17A7 (Glutamate transporter): CCATGACTAAGCACAAGACTC, AGATGACACCTCCATAGTGC.
Extraction of intracellular metabolites and Gas Chromatography-Mass Spectrometry. 
Astrocytes and MLD cultures were cultivated for 6 weeks in 12-well plates and washed with 1 ml of 
0.9% NaCl and quenched with 0.2 ml − 20 °C methanol. After adding an equal volume of 4 °C cold water, 
cells were collected with a cell scraper and transferred in tubes containing 0.2 ml −20 °C chloroform. 
The extracts were shaken at 1400 rpm for 20 min at 4 °C (Thermomixer Eppendorf) and centrifuged 
at 16,000 × g for 5 min at 4 °C. 0.2 ml of the upper aqueous phase was collected in specific glass vials 
with micro inserts and evaporated under vacuum at − 4 °C using a refrigerated CentriVap Concentrator 
(Labconco).
Metabolite derivatization was performed using a Gerstel MPS. Dried polar metabolites were dissolved 
in 15 μ l of 2% methoxyamine hydrochloride in pyridine at 40 °C under shaking. After 60 min an equal 
volume of MTBSTFA was added and held for 60 min at 40 °C. 1 μ l sample was injected into an SSL 
injector at 270 °C in splitless mode. GC/MS analysis was performed using an Agilent 7890A GC equipped 
with a 30 m DB-35MS + 5m Duraguard capillary column. Helium was used as carrier gas at a flow rate of 
1.5 ml/min. The GC oven temperature was held at 100 °C for 2 min and increased to 300 °C at 10 °C/min. 
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After 3 min, the temperature was increased to 325 °C. The GC was connected to an Agilent 5975C inert 
XL MSD, operating under electron ionization at 70 eV. The MS source was held at 230 °C and the quadru-
pole at 150 °C. The detector was operated in scan mode with mass range m/z 70–800. The total run time 
of one sample was 25.00 min. All GC/MS chromatograms were processed by using MetaboliteDetector25. 
Mass isotopomer distributions (MIDs) were determined and corrected for natural isotope abundance 
using MetaboliteDetector (Hiller et al., 2009). For determination of MIDs the following ions were selected 
(Wegner et al., 2014): Asparatate_3TBDMS: 418–427; Citrate_4TBDMS: 591–601; Glutamate_3TBDMS: 
432–442; Serine_3TBDMS: 390–397; Glycine_2TBDMS: 246–252; Lactate_2TBDMS:261–269.
Electrophysiology. For electrophysiological recordings coverslips with hNSC derived neurons were 
transferred to a recording chamber mounted on an upright microscope (Zeiss, Oberkochen, Germany) 
and kept in a bath solution containing (in mM): NaCl 130, KCl 3, NaHCO3 10, CaCl2 1.5, MgCl2 
1, Glucose 11, HEPES 10, pH 7.3 with NaOH. Patch pipettes with 2− 4 M were filled with (in mM) 
K-gluconate 125, KCl 20, EGTA 0.5, MgATP 4, MgCl2 4, Na2GTP 0.3, HEPES 10, pH 7.4 with KOH. 
Measurements were done with an EPC10 amplifier and Patchmaster software (HEKA, Lambrecht, 
Germany). For puff-application of KCl or glutamate, a pipette with 15 μ m tip diameter was placed 
60–100 μ m away from the recorded cell. Pressure ejection was controlled by a pico pump (PV830, WPI, 
Sarasota, FL).
Measurement of Glutamate Uptake. Astrocytes DIV 80–90 and HEK 293 cells were incubated for 
10 minutes at 37 °C in basic media containing 50 M of L-glutamic acid (Sigma). Glutamate uptake was 
measured using a colorimetric kit (abcam) according to manufacturer’s instructions. Absorbance meas-
urements were normalized to total protein per culture well.
Mice. 12 week old male NOD/SCID mice were kept under standard conditions according to govern-
mental rules and regulations. All experiments have been conducted according to the German Animal 
Welfare Act and have been approved by the responsible authorities (Landesamt für Natur, Umwelt und 
Verbraucherschutz Nordrhein-Westfalen). For each transplantation approach, 3 animals were used.
hNSC transplantation. For stereotactic injections, mice were under deep anesthesia (intraperitoneal 
injection of 17 μ l of 2.5% Avertin per gram of body weight) and fixed into a stereotactic frame (Kopf). 
Three microlitres of cell suspension (in total: 1 × 105–2 × 105 cells) were injected into the lateral ventricle 
over 5 minutes using a Hamilton 7005KH 5μ l syringe. Following stereotactic coordinates in relation to 
bregma were used: anteroposterior: 1.4 mm, mediolateral: ± 0.84 mm, dorsoventral: − 2.5 below skull. In 
order to control the hNSC fate after transplantation, we introduced an in vitro pre-differentiation step in 
our experimental set-up. At the first step, passage 6 or higher hNSCs were splitted in a 1:2 ratio. Three 
days later, the hNSC maintenance medium in one of the dishes was changed to neuronal differentiation 
medium, while the second dish was subjected to astroglial differentiation by replacing the maintenance 
medium by glial differentiation medium. After one week of pre-differentiation, 1 × 106 to 2 × 106 cells 
were transplanted into the brain of adult NOD/SCID mice. The cell fate was analyzed 6 additional weeks 
later.
Perfusion, sectioning and immunohistochemistry. Mice under deep anesthesia were perfused 
with 50 ml PBS following 50 ml 4% PFA/1 PBS solution. After dissection, isolated brains were post-fixed 
in 4% PFA/1 PBS solution over night at 4 °C. 40 μ m sagittal brain sections were cut using a Vibratom 
(Leica VT 1200 S). Free-floating sections were permeabilized in Tris-buffered saline solution with 0.1M 
Tris, 150mM NaCl, pH 7.4/0.5% Triton-X 100/0.1% Na-Azide/0.1% Na-Citrate/5% normal goat serum 
(TBS+ /+ /+ ) for at least 1 h. The primary antibodies anti-Hu Nuclei (1:200; Millipore), anti-DCX (1:400; 
Abcam), anti-TuJ1 (1:600; Covance) and anti-GFAP (1:100; Millipore) were diluted in TBS+ /+ /+ and 
incubated for 48 h on a shaker at 4 °C. For immunofluorescence staining, secondary Alexa-fluorophore 
conjugated antibodies (Invitrogen) and Hoechst 33258 (1:10000, Invitrogen) were used. Sections were 
analyzed with a Zeiss LSM 710 confocal microscope.
Statistical analysis. Data presented are means ± SEM. Statistical significance was tested with Sigma 
Plot software. Results were denoted statistically significant when p values were < 0.05; number (n) of 
samples/repeats are given in the Results and Figure legends.
Results
Newly generated hNSCs conserved self-renewing characteristics. We maintained human iPSCs 
on mouse embryonic fibroblasts (MEFs) or under feeder free conditions, and treated them according to 
the scheme in Fig. 1a. As described previously12, the neural induction of embryonic bodies from hiPSC 
(Fig. 1b,c) was achieved by inhibition of BMP and TGFß signaling26,27. Simultaneously, we administered 
CHIR99021 and Purmorphamine to stimulate the canonical WNT- and SHH-pathways28,29. These neu-
ral-induced embryonic bodies (Fig. 1c) were cultivated under defined conditions until neural tube like 
structures appear (Fig.  1d). Neural rosette-like structure formation was induced by supplementing the 
culture medium with bFGF3 for four additional days (Fig. 1e). After re-plating, the cells were cultured 
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Figure 1. Generation of human neural stem cells (a) Schematic representation for directed differentiation of 
iPSC cells to hNSC. (b–g) Phase contrast of images of the generation of hNSC. (b) Feeder-free hiPSC.  
(c) Embryonic bodies after 3 days of differentiation. (d) Tube like structures after six days of differentiation.  
(e) Induction of neural rosette formation at day 10. (f) First passage of hNSCs at day 14 of hiPSC 
differentiation; (g) heterogeneous cell population becomes homogeneous after several passages. hNSC. (h–s) 
Immunofluorescence labeling of the neural stem cell markers Nestin, Sox2, Sox1 and Pax6 as well as of the cell 
cycle marker Ki67 of hNSCs at Passage 3 (h,k,n,q), Passage 6 (i,l,o,r) and Passage 27 (j,m,p,s). Scale bar 10 μ m.
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in presence of EGF, bFGF, N2, B27 and hLIF. Following the first passages, the initially heterogeneous 
cell clusters adopted a homogeneous morphology (Fig. 1f,g). Induction of differentiation into either the 
neuronal or the glial lineage (details see below) induced further changes in morphology.
One key characteristic of neural stem cells is their extensive self-renewal potential. This ability was 
evaluated by measuring the cell number over the first 21 passages following their generation. The resulting 
exponential growth curve showed stable proliferation rates over the 21 passages analyzed (Figure S2a). 
To confirm that generated hNSCs preserved self-renewing characteristics, we evaluated the presence of 
the stem cell markers Nestin, Sox2, Sox1 and Pax6 at early (passage 3 and 6) and late (passage 27) pas-
sages (Fig. 1h–p). While Nestin, Sox1 and Sox2 showed very similar expression patterns, Pax6 displayed 
cytoplasmic labeling at lower passage numbers and more nuclear labeling at higher passages (Fig. 1n–p), 
which is in agreement with data on brain development30. Finally, we observed that hNSCs maintained 
proliferation characteristics, as demonstrated by the positive labeling of the cell cycle marker Ki67 across 
passages (Fig. 1q–s). These results demonstrate that generation and maintenance of hiPSC-derived hNSCs 
was achieved robustly, and that hNSCs maintained self-renewing characteristics over numerous passages.
hNSCs revealed distinct gene expression profile. In order to further characterize the generated 
hNSCs, we compared the mRNA transcriptome of hiPSCs, and hNSCs derived from these progenitors 
(Fig. 2). Additionally, we included differentiated cells, derived from these hNSCs in the analysis. Since the 
induced differentiation was undirected, multiple cell types were present in this population; consequently 
we consider this a multilineage differentiation (hMLDCs) (Figure S1). To minimize the interlineage 
differences existing between iPSC-lines generated from different individuals31, we based our comparison 
on hiPSCs, hNSCs and hMLDCs derived from the same individual. The transcriptome-based corre-
spondence analysis (CoA) of the three cell types demonstrated that hiPSCs, hNSCs and hMLDCs were 
characterized by distinct molecular expression signatures (Fig. 2a).
The paired comparison of hiPSCs and of hNSCs in a scatter blot highlights that neural-stem-cell-genes 
(Pax6, Sox1 and Nestin) were higher expressed in hNSCs when compared to their parental hiPSCs. 
Similarly, hNSCs showed a significant downregulation of the pluripotency genes Lin28a, Nanog and Oct4 
(Fig. 2b and Figure S2b). RT-qPCR analysis comparing the expression levels of the pluripotency genes 
Oct4 and Nanog as well as the neural-stem-cell-gene Nestin between hiPSCs and hNSCs confirmed 
these data (Fig. 2c). Interestingly, the neural stem cell specific marker Nestin was found nearly absent in 
hiPSCs when compared to hNSCs. The marker Sox2, predicted to be strongly expressed within pluripo-
tent1 and neural stem cells32, as well as the proliferation marker Ki67, exhibited similar expression levels 
within hiPSCs and hNSCs.
We further isolated 1428 transcripts that differed at least twofold between hNSCs, hiPSCs and 
hMLDCs. The resulting Gene Ontology (GO) analysis revealed that genes specifically expressed in 
hNSCs were mainly involved in the biological processes development, differentiation, neurogenesis and 
cell adhesion (Fig. 2d). In order to better decipher key mechanisms important for hNSC maintenance, 
we performed a network analysis on the “biological-process GO-terms” that were statistically associated 
with the 1428 enriched hNSCs genes. Within the GO-Network, we observed that the GO terms clus-
tered as sub-networks that may be outlined as “Tissue development”, “Cell growth and differentiation”, 
“Neurogenesis and neuron development”, “Regulation of catabolism and metabolism” and “Regulation 
of BMP signaling pathway” (Fig.  2e). We also compared the transcriptional profiles of hiPSCs, hNSCs 
and hMLDCs and identified the genes differentially regulated in the 3 groups (Table S1 and Figure S3). 
By this approach, we were able to define a unique expression signature that clearly distinguished hNSCs 
from less differentiated hiPSCs as well as from the more differentiated hMLDCs.
hNSCs differentiated into mature astrocytes. In the next step we wanted to demonstrate the abil-
ity of hNSCs to differentiate into astrocytes. The astrocytic differentiation medium consisted of the basic 
cultivation medium supplemented with 1%FCS. The most commonly used marker protein for astrocytic 
differentiation is GFAP. However, astrocytes positive for GFAP are considered to show a reactive phe-
notype while astrocytes negative for GFAP show a quiescent phenotype with protoplasmic morphology, 
as described previously33. We therefore used the additional markers S100β and vimentin to investigate 
astrocyte differentiation.
After 45–50 days of differentiation, we observed that nearly 100% of the cells were expressing S100β 
(Fig.  3a). After 60 days, some astrocytes showed GFAP immunoreactivity while all the cells expressed 
vimentin (Fig. 3b–d). S100ß was expressed in 100% of the cells also at this time point (Fig. 3f–h). The 
contamination with neurons was negligible as shown by the Tuj1 staining (Fig. 3e). We further observed 
that after 60 days of differentiation, some cells still expressed the proliferation marker Ki67 (Fig.  3g), 
indicating that they are able to proliferate, a capacity shared with primary astrocytes34,35. In support, 
loss of neural stem cell- and proliferation markers with simultaneous increase of glial markers was also 
observed by RT-qPCR. Nestin and Ki67 were significantly downregulated upon 45 days of glial differen-
tiation and we observed a massive increase in the expression levels of GFAP gene (Fig. 3i).
Remarkably, after 60 days of differentiation all astrocytes also expressed a basal level of AQP4 (Fig. 4a), 
a marker for the main water channel in the perivascular membranes, typically present in astrocytic end-
feet in brain tissue. Additionally, they expressed the glutamate transporter EAAT2 (Fig. 4b) that is used 
by astrocytes in situ to remove glutamate from the extracellular space. This is a key function of mature 
www.nature.com/scientificreports/
7Scientific RepoRts | 5:16321 | DOi: 10.1038/srep16321
Figure 2.  Molecular Characterization of hNSCs (a) Multi-Dimensional Scale analysis based on the mRNA 
transcription profiles of hiPSCs (blue), hNSCs (yellow) and hMLDCs (red). All profiled cell-types were 
generated from the same individual. (b) mRNA scatter blot of hiPSCs and hNSC; hNSC specific genes 
(red), hiPSC specific genes (green), genes observed in both cell types (black). (c) mRNA expression levels 
of OCT4, Nanog, Ki67, SOX2 and Nestin in hiPSC and hNSC quantified by RT-qPCR. (d) Gene Ontology 
analysis based on the 1428 genes specifically expressed in hNSCs when compared to hiPSCs and hMLDCs. 
(e) GO terms were subjected to a network analysis based on ReviGO (http://revigo.irb.hr/) and CytoScape 
(http://www.cytoscape.org/) softwares. The main GO sub-clusters are highlighted.
www.nature.com/scientificreports/
8Scientific RepoRts | 5:16321 | DOi: 10.1038/srep16321
Figure 3. Rapid generation of hNSC derived astrocytes. Representative confocal images illustrating the 
expression of astrocytic markers (a) S100β after 50 days of differentiation, (b–d) GFAP-vimentin, (e) Tuj1-
vimentin, (f–h) S100β -Ki67. (i) mRNA expression levels of Nestin, Ki67, GFAP in hNSC and astrocyte 
quantified by RT-qPCR.
Figure 4. Astrocytes displayed mature functions. Representative confocal images illustrating the expression 
of astrocytic markers (a) AQP4 and (b) EAAT2 after 60 days of differentiation. Scale bars 50 μ m.  
(c) Glutamate up-take in astrocytes DIV 80–90 and HEK 293. Mean ± SEM; n = 3 indipendent experiments.
www.nature.com/scientificreports/
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astrocytes36 that was also confirmed by a glutamate uptake assay (Fig. 4c). Astrocytes differentiated for 
80–90 days were able to transport glutamate intracellularly. We assessed HEK 293 as a cell type with no 
specific glutamate intake ability (p = 0,016, Student t test).
Our results demonstrate that by replacing the hNSC maintenance medium with the adequate differ-
entiation medium it was possible to induce a robust and homogenous differentiation into astrocytes. The 
homogeneous immunoreactivity toward AQP4 and EAAT2 and the ability to transport glutamate suggest 
that hNSC-derived astrocytes reached a certain level of maturity and functionality.
Astrocytes showed increased pyruvate carboxylase activity and reduced serine biosynthe-
sis. A hallmark of astrocytes is the presence and the relative high activity of the metabolic enzyme 
pyruvate carboxylase (PC)37. PC catalyzes the carboxylation of pyruvate to the tricarboxylic acid cycle 
(TCA) intermediate oxaloacetate. This reaction is important during anabolic processes to replenish 
the TCA cycle with oxaloacetate. To investigate the presence and the activity of pyruvate carboxylase 
in hNSCs derived astrocytes we used uniformly labeled [U-13C]glucose to monitor the fate of glucose 
in astrocytes. Application of this stable isotope tracer results in isotopic enrichment in all metabolites 
downstream of the tracer (e.g. metabolites of the glycolysis and the TCA cycle). The isotopic enrichment 
can be measured using Gas Chromatography/Mass Spectrometry. In case pyruvate is oxidized via pyru-
vate dehydrogenase to acetyl-coA the succeeding citrate molecule shows a mass enrichment by two (M2 
isotopologue). In case of pyruvate carboxylation by PC the succeeding citrate molecule shows a mass 
enrichment by three (M3 isotopologue). M5 citrate isotopologues result from both, pyruvate dehydro-
genase and PC activity (Fig. 5a).
Using this approach, we compared pure astrocyte cultures with multi-lineage differentiation cultures 
(MLDCs) and we observed increased PC activity in the pure astrocyte culture (17% enrichment vs. 4% 
enrichment of M3 aspartate) (Fig. 5b). We also observed increased M3 and M5 isotopologue abundance 
of citrate originating from M3 oxaloacetate as the precursor (Fig. 5c). To compare the amount of glucose 
contributing to the citrate pool, we calculated the total carbon contribution from glucose to citrate in 
both culture conditions (Fig.  5d). We determined 24% glucose carbon contribution to citrate in pure 
astrocyte cultures and only 15% glucose carbon contribution in MLDCs. This difference was also visible 
in glutamate (Fig. 5d,e). In summary, these data show increased PC activity and glucose derived carbon 
contribution into the TCA cycle in astrocytes compared to MLDCs.
Besides glucose, the amino acid glutamine represents the most important carbon source for cells. 
This is especially pronounced in proliferating cells or in any cell type with increased anabolic demands38. 
To evaluate the impact of glutamine to the TCA cycle of astrocytes we used uniformly labeled [U-13C]
glutamine and investigated the isotopic enrichment in citrate. In the astrocyte cultures we found that 
glutamine provided similar amounts of carbons for the synthesis of citrate as glucose (22%) (Fig.  5d). 
However, in MLDCs (where the glucose contribution was lower as in astrocytes) we found an increased 
contribution from glutamine (34%), probably to compensate for the decreased glucose contribution. In 
line with increased glutamine derived carbon contribution we also found higher M4 and M5 istopologue 
abundances of citrate (Fig. 5f).
Furthermore we identified also unexpected features of astrocyte metabolism compared to MLDCs. By 
using [U-13C]glucose we found clear differences in the MID of serine. This non-essential amino acid can 
be derived from 3-phosphoglycerate, an intermediate of the glycolysis (Fig. 6a). As an alternative to de 
novo biosynthesis it can be taken up from the medium. Based on stable isotope experiments we found 
higher relative serine biosynthesis rates in MLDCs (24%) as in pure astrocyte cultures (5%) (Fig. 6b,c) 
where most serine originated from the medium (M0 isotopologue abundance). Interestingly, although 
we found at least 5% (astrocytes) and 24% (MLDCs) of relative glucose contribution to serine, there 
was very little labeling in glycine (Fig. 6d). This indicated that the equilibrium of the SHMT catalyzed 
reaction is far on the side of serine and that most glycine is taken up from the medium rather than being 
synthesized from glucose.
Similar to serine, we also found increased labeling in lactate (M3) in MLDCs (Fig. 6e). Lactate has 
an important role in maintaing the cytosolic redox balance of NADH/NAD+. The reason for different 
lactate labeling patterns could be caused by two reasons: first, pure astrocyte cultures might consume 
more (unlabeled) pyruvate from the medium (present at 1mM concentration) resulting in higher M0 
abundance and second, pyruvate and thus lactate might be produced from serine via serine dehydratase. 
Whether this function plays a role in glial metabolism needs further investigation.
hNSCs differentiated into various neuronal subtypes. Although we here focus on astrocyte dif-
ferentiation, the ability to differentiate into neurons is a hallmark of NSCs and therefore needs to be 
evaluated for the characterization. To induce neuronal differentiation in our hNSC culture system a 
treatment with the factors BDNF (brain-derived neurotrophic factor), GDNF (glial cell line-derived neu-
rotrophic factor), TGFB-3 (transforming growth factor beta-3), dbcAMP (dibutyryl-cAMP) and ascorbic 
acid was used. After 4 weeks of neuronal differentiation, derived cells showed positive labeling for early 
neuronal markers such as TuJ1 and Doublecortin (Figure S4a and b) as well as for the advanced matu-
ration marker MAP2 (Figure S4c). The neuronal differentiation protocol enabled hNSCs to differenti-
ate into GABAergic (GABA, 36.21%), glutamatergic (vGlut1, 40.34%) and dopaminergic neurons (TH, 
12.68%) (Figure S4d–f), whereas differentiation into GFAP-positive cells was low (Figure S4g).
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To test these results at the mRNA level, we used RT-qPCR to quantitate expression of the neural 
stem cell marker Nestin, the proliferation marker Ki67, the neuronal marker MAP2, as well as the 
neuronal sub-type markers for GABAergic (GABA), glutamatergic (GLUT, vGlut1) and dopaminergic 
(TH) neurons. This analysis was performed in a comparison of hNSC under maintenance conditions 
and after 4 weeks of neuronal differentiation (Figure S4h). The results demonstrate that neural stem 
cell identity and proliferation capacities decreased with differentiation. At the same time, we observed 
Figure 5. Stable isotope assisted metabolic profiling of hNSCs derived astrocyte. (a) Atom transition 
model of uniformly labeled [U-13C]glucose. Glucose derived [U-13C]pyruvate can enter the TCA cycle 
via pyruvate dehydrogenase (PDH) dependent oxidation of pyruvate to acetyl-coA. In this case citrate 
molecules show a mass increase by two (M2 isotopologue). Subsequent TCA cycle metabolites are also 
M2 isotopologues. As an alternative way to enter the TCA cycle pyruvate can be carboxylated by pyruvate 
carboxylase, resulting in oxaloacetate M3 isotopologues. The dotted line indicates the start and the end 
of the cycle. ALAT: alanine aminotransferase; LDH: lactate dehydrogenase; PC: pyruvate carboxylase; CS: 
citrate synthase; ACO: Aconitase; IDH: isocitrate dehydrogenase; GDH: glutamate dehydrogenase; AT: 
aminotransferase; SDH: succinate dehydrogenase; FH: fumarate hydratase; MDH: malate dehydrogenase. 
(b–f) Mass isotopomer distributions (MIDs) and carbon contributions. Cells were labeled for 24h prior 
extraction of intracellular metabolites and analysis by GC/MS. M1-M6 indicates the number of 13C atoms 
incorporated into the metabolite. (b) MID of aspartate using [U-13C]glucose as a tracer. (c) MID of citrate 
using [U-13C]glucose as a tracer. (d) Calculated carbon contribution from gluocose, glutamine and other 
carbon sources (e.g. lipids, branched chain amino acids) to citrate (left) and glutamate (right). (e) MID of 
glutamate using [U-13C]gl = 3 independent experiments in triplicate; p-value < 0.05.
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increased expression levels of MAP2, GABA, vGlut1 and TH (Figure S4h), indicating ongoing neuronal 
differentiation.
To examine whether these neurons were functional, we performed immunolabelling for synaptic 
markers after 4 weeks of differentiation. We reliably detected the pre- and postsynaptic markers syn-
aptophysin and PSD95 (Figure S5a–d and S5e−h), consistent with the expression of a more mature 
neuronal phenotype. Next, we performed whole-cell patch-clamp recordings following standard pro-
cedures. Under voltage clamp conditions, neurons showed a fast transient inward current in response 
to depolarizing voltage steps (− 1.9 ± 0.4 nA, n = 30; Figure S5i) that was identified as a sodium (Na+-) 
current by blocking its influx with 0.5 μ M TTX (Figure S5j). The transient Na+-current was followed by 
an outward current with partial inactivation, typical for a mixture of voltage activated potassium chan-
nels. This outward current included an A-current that was identified in 10 out of 12 cells tested with 
a pre-pulse protocol (data not shown). The input resistance of the induced neurons was 1.5 ± 0.2 GΩ 
(n = 33). The amount of sodium current as well as the input resistance are typical for mature neurons39,40. 
In current clamp recordings, cells showed spontaneous action potential (AP) firing, when depolarized 
to a membrane potential near − 50 mV by current injection (Figure S5k). Depolarizing currents elicited 
APs with + 19 ± 5 mV peak potential (n = 15 cells; Figure S5l) and a width at half-maximal amplitude 
of 3.8 ± 0.1 ms (n = 10). While the generation of APs is an important aspect of the neuronal lineage, we 
observed no spontaneous postsynaptic currents in continuous voltage clamp recordings (> 3 min per 
cell; n = 30). Similarly, evoked postsynaptic currents could not be elicited by moderate depolarization 
with KCl applied in bath solution (10 mM; n = 5) or by puffs with high KCl (150 mM; 1–5 s duration; 
n = 6) directly onto patched cells. In contrast, puff-application of glutamate (1 mM, 0.5 s) elicited inward 
currents (608 ± 362 pA; n = 4) under voltage clamp conditions (Figure S5m), or depolarizations to mem-
brane potentials near 0 mV (n = 4) during current clamp (Figure S5n). These data indicate the presence 
of typical sodium channels and glutamate receptors in differentiated hNSCs cells, however, they also 
Figure 6. Stable isotope assisted metabolic profiling reveals differences in serine biosynthesis in hNSCs 
derived astrocytes and hNSCs derived MLDC. (a) Cartoon illustrating possible atom transitions for serine 
in respect to the reversibility of the enzyme serine hydroxy methyl transferase (SHMT) and potential 
metabolic fates for serine. The hydroxymethylgroup of serine is transferred on tetrahydrofolate resulting in 
M2 glycine isotopologues. In the reversible reaction serine can be M0, M1, M2 or again M3 depending on 
the combination of labeled and unlabeled metabolite. (b) MID of serine using [U-13C]glucose as a tracer. 
(c) Carbon contribution of glucose to serine. Glutamine has no contribution to the serine pool (data not 
shown) (d) MID of glycine using [U-13C]glucose as a tracer. (e) MID of lactate using [U-13C]glucose as a 
tracer. Mean ± SEM, n = 3 independent experiments in triplicate; p-value < 0.05.
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indicate that the synaptic release machinery is still incompletely developed, requiring more research into 
the specific factors regulating its differentiation.
Transplanted hNSCs survived and differentiated in vivo. Finally, we aimed at characterizing 
hNSC derived cells in vivo. The use of hiPSC-derived cells mandates that firstly, transplanted cells are 
devoid of tumor formation potential, and secondly, the transplanted cells are able to survive in vivo. 
Since the potential of tumor formation is inversely correlated to the degree of differentiation, we selected 
cells after 6 passages for transplantation because nearly all hNSCs were Nestin-positive and Oct4-/
Nanog-negative at this time point. Stereotactic injection of self-renewing hNSCs into the subventricular 
zone of NOD/SCID mice was never followed by any tumoral growth. In total, 1 × 106 to 2 × 106 hNSCs 
were transplanted into the brain hemispheres of 9 mice. 3 mice were sacrificed after 6 weeks, 3 other 
mice were sacrificed after 3 month and the final 3 mice were sacrificed after 6 months. In none of these 
mice, we observed tumoral outgrowth.
To control cells fate after transplantation, hNSC were subjected to a pre-differentiation step. The cell 
fate was analyzed 6 additional weeks later (Fig. 7a). Since injected cells were of human origin, the trans-
plant could be identified by immunofluorescence with a specific antibody directed against human nuclei 
(hNuc). Human NSCs that were neuronal pre-differentiated one week before transplantation, were able 
to survive and to differentiate into TuJ1 (Figure S6c) and Doublecortin (Figure S6g) positive neurons. 
hNSCs that were differentiated to astroglia for 1 week prior transplantation formed clusters of GFAP 
positive astrocytes (Fig. 7d).
These data demonstrate that pre-differentiation prior to transplantation can direct the fate of trans-
planted cells after grafting. The ability to define the fate of cells after transplantation is of outstanding 
importance for controlled cell replacement therapies. Thus the here described hNSC system may pro-
vide a basis for further investigations aiming at the development of strategies for future therapeutic 
approaches.
Figure 7. Transplantation of hNSC derived neurons and astrocytes in NOD/SCID mice. (a) Schematic 
representation of the protocol followed. hNSC were kept in maintenance medium for 3 days after splitting. 
Then the maintenance medium was switched to glial differentiation medium. Stereotactic injection into the 
subventricular zone of NOD/SCID mice was performed 7 days later. Representative images showing that 
clusters of GFAP positive cells formed by pre-differentiated hNSC (b–e). Drawings were produced using 
Servier Medical Art (www.servier.com; http://creativecommons.org/licenses/by/3.0/).
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Discussion
In this manuscript, we describe a novel protocol for the generation of hNSCs from hiPSCs. This fate 
transition is achieved by the chronological administration of media with defined compositions. The here 
presented protocol is very robust and independent of any sorting method. In contrast to other proto-
cols for the generation of human neural precursor cells, no small molecules were needed for keeping 
hNSCs under self-renewing condition12,41–43. Differently to previous studies where neural progenitors 
grow and proliferate as neurospheres44 or neural rosettes45, hNSCs were homogeneously maintained in 
a two-dimensional adherent cell system. Spontaneous differentiation of hNSC into other cell types was 
negligible. hLIF in the media blocked fate transition of hNSC into neuronal cells. Although hLIF has 
been reported to induce astrocytes differentiation in synergy with bone morphogenetic protein (BMP) 
2 from mouse neuroepithelial cells46, we did not detect significant amounts of GFAP-positive cells in 
the hNSC under maintenance condition. The beneficial effect of LIF has been previously observed in 
human neural progenitor cells in terms of prevention of apoptosis by inhibition of caspase 3 and 7 47. LIF 
also provided protection against reactive oxygen species and enhanced cell proliferation47. These effects 
have shown to be driven by the activation of JAK-STAT3 (Janus kinase-Signal transducer and activator 
of transcription 3) and MEK (MAPK/ERK kinase) pathways in non-neural stem cells such as mouse 
embryonic stem cells48 and human neural progenitor cells47.
The here described cells conserved the two main characteristics of neural stem cells, i.e. self-renewing 
and multi-linear differentiation capacities. Since they grow in homogenous cultures, these cells are an 
attractive tool for expression profiling, disease modeling and high content screenings. Besides their abil-
ity to differentiate into functional neurons, hNSCs differentiated into glial cells within a relatively short 
time period. In this study, we determined a gene expression profile that distinguishes hNSC from less 
differentiated hiPSC and more differentiated neurons and astrocytes. Since these profiles were generated 
from cells from the same individual (starting iPSC line), the degree of comparability is very high and the 
derived signatures should purely represent the differentiation status.
Several papers described the generation of human astrocytes from fetal or adult post-mortem central 
nervous system by the expansion of neuronal precursors49,50. This approach required 6 months to gener-
ate a pure population of astrocytes51. Other recent papers described the differentiation of astrocytes from 
iPSC with protocols requiring from 35 days52 up to 4 months53. Importantly, the obtained populations 
seem to represent astrocytes just in a reactive form as shown by the almost 100% immunoreactivity for 
GFAP. Therefore, these cultures might not be suitable to completely model mature astrocyte functions or 
to mirror patho- and physiological conditions33.
In the here presented study, the derivation of astrocytes was achieved by a cost-efficient media compo-
sition, which ensures a highly pure culture as shown by the negligible contamination with Tuj1 positive 
cells. Unlike other protocols54, our protocol is simple and does not require any antibody-based sorting 
step of glia or neuronal progenitors. Remarkably, we were able to obtain a population of mature astrocytes 
both in a quiescent state with a protoplasmic morphology (negative for GFAP) as well as in a reactive 
phenotype characterized by GFAP expression. The expression of EAAT2 in all the cells and the ability to 
uptake glutamate strongly supported the acquisition of mature functions. The importance of this feature 
was highlighted by the different effects of immature and mature astrocytes on axonal regeneration55,56.
The high pyruvate carboxylase activity confirmed the acquisition of metabolic specialization of 
hNSC-derived astrocytes as pyruvate carboxylation is an important anaplerotic reaction, specifically 
occurring in astrocytes57,58. Moreover, the relative glucose flux into the TCA cycle was higher in astro-
cytes resulting in higher glucose derived carbon contribution to glutamate59. Very interestingly, in astro-
cytes as well as MLDCs around 50% of the citrate carbons derived from other sources than glucose or 
glutamine. These other sources might be represented by lipid oxidation and/or degradation of amino 
acids such as branched chain amino acids. Compared to other cell lines 50% of carbons derived from 
alternative carbon sources is relatively high, at least at basic culture conditions and high oxygen tension 
(unpublished data). The reasons for that can be multiple and should be investigated in future research. 
Identifying the relevance of alternative carbon sources for glial specific metabolism could help for a 
better understanding of cell survival and integrity.
Particularly interesting is the role of serine as it represents an important metabolic intersection point 
to i) provide one-carbon units to the folate mediated one-carbon metabolism, to ii) serve as a precursor 
for the transsulfuration pathway to generate cysteine from serine and homocysteine and iii) as the pre-
cursor to produce the non-essential amino acid glycine. Serine and its connected metabolic pathways 
have been shown to be of special importance in neuronal oxidative stress conditions60. Astrocytes have an 
important supportive function in protecting neurons against oxidative stress by providing the antioxidant 
glutathione61. Glycine represents together with cysteine and glutamate one of the three amino acids that 
build the antioxidant glutathione.
Recently, the outstanding importance of astrocytes for neurological disease got into focus of several 
research approaches. As an example, it has been shown that astrocytes strongly contribute to the devel-
opment of the Down syndrome62. Additionally, a recent study clearly demonstrated that transplantation 
of astrocytes was extremely beneficial in a rat model of Parkinson’s disease63. Thus, the availability of an 
effective method to generate mature astrocytes, as described in this study, is of key importance for con-
vincing disease-modelling studies and replacement therapy strategies. This is becoming a relevant field 
of investigation especially for neurodegenerative diseases such as Parkinson´s and Alzheimer´s disease.
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